ANGX vs NMAX

The company exhibits severe financial distress with a Piotroski F-Score of just 2/9, indicating weak fundamental health. Despite explosive year-over-year revenue growth of 280.4%, the business is deeply unprofitable with a -53.77% profit margin and a catastrophic ROE of -440.92%. Valuation metrics are stretched, with a Price/Book of 23.10 and a negative Forward P/E, while cash flow and balance sheet data are unavailable, raising transparency concerns. Although analysts recommend a 'strong_buy', the underlying financials suggest high risk and limited near-term viability.

NMAX exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total lack of fundamental improvement across all health metrics. Despite maintaining a low debt-to-equity ratio and acceptable liquidity, the company is suffering from severe profitability collapse with an ROE of -205.18% and a profit margin of -52.57%. The stock has experienced a catastrophic long-term decline, losing 92.5% of its value over five years. While analyst target prices suggest a significant upside, the deterministic data points to a high-risk profile with no current evidence of a sustainable turnaround.